1
|
Hübner JL, Lucchetti LEB, Nong HN, Sharapa DI, Paul B, Kroschel M, Kang J, Teschner D, Behrens S, Studt F, Knop-Gericke A, Siahrostami S, Strasser P. Cation Effects on the Acidic Oxygen Reduction Reaction at Carbon Surfaces. ACS Energy Lett 2024; 9:1331-1338. [PMID: 38633991 PMCID: PMC11019649 DOI: 10.1021/acsenergylett.3c02743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Revised: 02/13/2024] [Accepted: 02/14/2024] [Indexed: 04/19/2024]
Abstract
Hydrogen peroxide (H2O2) is a widely used green oxidant. Until now, research has focused on the development of efficient catalysts for the two-electron oxygen reduction reaction (2e- ORR). However, electrolyte effects on the 2e- ORR have remained little understood. We report a significant effect of alkali metal cations (AMCs) on carbons in acidic environments. The presence of AMCs at a glassy carbon electrode shifts the half wave potential from -0.48 to -0.22 VRHE. This cation-induced enhancement effect exhibits a uniquely sensitive on/off switching behavior depending on the voltammetric protocol. Voltammetric and in situ X-ray photoemission spectroscopic evidence is presented, supporting a controlling role of the potential of zero charge of the catalytic enhancement. Density functional theory calculations associate the enhancement with stabilization of the *OOH key intermediate as a result of locally induced field effects from the AMCs. Finally, we developed a refined reaction mechanism for the H2O2 production in the presence of AMCs.
Collapse
Affiliation(s)
- J. L. Hübner
- Department
of Chemistry, Chemical Engineering Division, Technical University of Berlin, 10623 Berlin, Germany
| | - L. E. B. Lucchetti
- Centro
de Ciências Naturais e Humanas, Federal
University of ABC, Bairro Bangu, 09210-170 Santo André, Brazil
| | - H. N. Nong
- Department
of Chemistry, Chemical Engineering Division, Technical University of Berlin, 10623 Berlin, Germany
| | - D. I. Sharapa
- Institute
of Catalysis Research and Technology, Karlsruhe
Institute of Technology, 76344 Eggenstein-Leopoldshafen, Germany
| | - B. Paul
- Department
of Chemistry, Chemical Engineering Division, Technical University of Berlin, 10623 Berlin, Germany
| | - M. Kroschel
- Department
of Chemistry, Chemical Engineering Division, Technical University of Berlin, 10623 Berlin, Germany
| | - J. Kang
- Department
of Chemistry, Chemical Engineering Division, Technical University of Berlin, 10623 Berlin, Germany
| | - D. Teschner
- Department
of Inorganic Chemistry, Fritz-Haber-Institute
of the Max-Planck-Society, 14195 Berlin, Germany
- Department
of Heterogeneous Reactions, Max-Planck-Institute
for Chemical Energy Conversion, 45470 Mülheim an der Ruhr, Germany
| | - S. Behrens
- Institute
of Catalysis Research and Technology, Karlsruhe
Institute of Technology, 76344 Eggenstein-Leopoldshafen, Germany
| | - F. Studt
- Institute
of Catalysis Research and Technology, Karlsruhe
Institute of Technology, 76344 Eggenstein-Leopoldshafen, Germany
| | - A. Knop-Gericke
- Department
of Inorganic Chemistry, Fritz-Haber-Institute
of the Max-Planck-Society, 14195 Berlin, Germany
- Department
of Heterogeneous Reactions, Max-Planck-Institute
for Chemical Energy Conversion, 45470 Mülheim an der Ruhr, Germany
| | - S. Siahrostami
- Department
of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A1S6, Canada
| | - P. Strasser
- Department
of Chemistry, Chemical Engineering Division, Technical University of Berlin, 10623 Berlin, Germany
| |
Collapse
|
2
|
Cernosek T, Jain N, Dalphin M, Behrens S, Wunderli P. Accelerated development of a SEC-HPLC procedure for purity analysis of monoclonal antibodies using design of experiments. J Chromatogr B Analyt Technol Biomed Life Sci 2024; 1235:124037. [PMID: 38335765 DOI: 10.1016/j.jchromb.2024.124037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Revised: 01/24/2024] [Accepted: 01/26/2024] [Indexed: 02/12/2024]
Abstract
The complex structure of biopharmaceutical products poses an inherent need for their thorough characterization to ensure product quality, safety, and efficacy. Analytical size exclusion chromatography (SEC) is a widely used technique throughout the development and manufacturing of monoclonal antibodies (mAbs) which quantifies product size variants such as aggregates and fragments. Aggregate and fragment content are critical quality attributes (CQAs) in mAb products, as higher contents of such size heterogeneities impact product quality. Historically, SEC methods have achieved sufficient separation between the high molecular weight (HMW) species and the main product. In contrast, some low molecular weight (LMW) species are often not sufficiently different in molecular mass from the main product, making it difficult to achieve appropriate resolutions between the two species. This lack of resolution makes it difficult to consistently quantify the LMW species in mAb-based therapeutics. The following work uses a design of experiments (DoE) approach to establish a robust analytical SEC procedure by evaluating SEC column types and mobile phase compositions using two mAb products with different physiochemical properties. The resulting optimized procedure using a Waters™ BioResolve column exhibits an improved ability to resolve and quantify mAb size variants, highlighting improvement in the resolution of the LMW species. Additionally, the addition of L-arginine as a mobile phase additive showed to reduce secondary interactions and was beneficial in increasing the recoveries of the HMW species.
Collapse
Affiliation(s)
- Terezie Cernosek
- Catalent Biologics, Madison, WI, USA; Keck Graduate Institute of Applied Life Sciences, Claremont, CA, USA.
| | | | | | - Sue Behrens
- Keck Graduate Institute of Applied Life Sciences, Claremont, CA, USA
| | | |
Collapse
|
3
|
Decker N, Johnson T, Behrens S, Obi N, Kaaks R, Chang-Claude J, Turzanski Fortner R. 30P Circulating 27-hydroxycholesterol, 25-hydroxycholesterol, and breast cancer prognosis. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Dittfeld C, Winkelkotte M, Behrens S, Schmieder F, Jannasch A, Matschke K, Sonntag F, Tugtekin SM. Establishment of a resazurin-based aortic valve tissue viability assay for dynamic culture in a microphysiological system. Clin Hemorheol Microcirc 2021; 79:167-178. [PMID: 34487029 DOI: 10.3233/ch-219112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND/AIM Tissue pathogenesis of aortic valve (AV) stenosis is research focus in cardiac surgery. Model limitations of conventional 2D culture of human or porcine valvular interstitial/endothelial cells (VIC/VECs) isolated from aortic valve tissues but also limited ability of (small) animal models to reflect human (patho)physiological situation in AV position raise the need to establish an in vitro setup using AV tissues. Resulting aim is to approximate (patho)physiological conditions in a dynamic pulsatile Microphysiological System (MPS) to culture human and porcine AV tissue with preservation of tissue viability but also defined ECM composition. MATERIALS/METHODS A tissue incubation chamber (TIC) was designed to implement human or porcine tissues (3×5 mm2) in a dynamic pulsatile culture in conventional cell culture ambience in a MPS. Cell viability assays based on lactate dehydrogenase (LDH)-release or resazurin-conversion were tested for applicability in the system and applied for a culture period of 14 days with interval evaluation of tissue viability on every other day. Resazurin-assay setup was compared in static vs. dynamic culture using varying substance saturation settings (50-300μM), incubation times and tissue masses and was consequently adapted. RESULTS Sterile dynamic culture of human and porcine AV tissue segments was established at a pulsatile flow rate range of 0.9-13.4μl/s. Implementation of tissues was realized by stitching the material in a thermoplastic polyurethane (TPU)-ring and insertion in the TIC-MPS-system. Culture volume of 2 ml caused LDH dilution not detectable in standard membrane integrity assay setup. Therefore, detection of resazurin-conversion of viable tissue was investigated. Optimal incubation time for viability conversion was determined at two hours at a saturated concentration of 300μM resazurin. Measurement in static conditions was shown to offer comparable results as dynamic condition but allowing optimal handling and TIC sterilization protocols for long term culture. Preliminary results revealed favourable porcine AV tissue viability over a 14 day period confirmed via resazurin-assay comparing statically cultured tissue counterparts. CONCLUSIONS Human and porcine AV tissue can be dynamically cultured in a TIC-MPS with monitoring of tissue viability using an adapted resazurin-assay setup. Preliminary results reveal advantageous viability of porcine AV tissues after dynamic TIC-MPS culture compared to static control.
Collapse
Affiliation(s)
- C Dittfeld
- Department of Cardiac Surgery, Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, Heart Centre Dresden, Dresden,Germany
| | - M Winkelkotte
- Department of Cardiac Surgery, Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, Heart Centre Dresden, Dresden,Germany
| | - S Behrens
- Fraunhofer Institute for Material and Beam Technology IWS, Dresden, Germany
| | - F Schmieder
- Fraunhofer Institute for Material and Beam Technology IWS, Dresden, Germany
| | - A Jannasch
- Department of Cardiac Surgery, Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, Heart Centre Dresden, Dresden,Germany
| | - K Matschke
- Department of Cardiac Surgery, Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, Heart Centre Dresden, Dresden,Germany
| | - F Sonntag
- Fraunhofer Institute for Material and Beam Technology IWS, Dresden, Germany
| | - S M Tugtekin
- Department of Cardiac Surgery, Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, Heart Centre Dresden, Dresden,Germany
| |
Collapse
|
5
|
Seibold P, Gao Y, Behrens S, Chang-Claude J. PH-0220 Long-term quality of life in breast cancer survivors 10 years after radiotherapy. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07272-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Maurer T, Jaskulski S, Behrens S, Jung AY, Obi N, Johnson T, Becher H, Chang-Claude J. Tired of feeling tired - The role of circulating inflammatory biomarkers and long-term cancer related fatigue in breast cancer survivors. Breast 2021; 56:103-109. [PMID: 33668004 PMCID: PMC7937559 DOI: 10.1016/j.breast.2021.02.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 01/26/2021] [Accepted: 02/15/2021] [Indexed: 01/16/2023] Open
Abstract
BACKGROUND Low-grade inflammation has been associated with cancer related fatigue (CRF). However, most studies focused on CRF during or shortly after treatment. Longitudinal studies are rare with inconsistent results. We assessed the association of inflammatory biomarkers with total CRF and all subdomains (physical, cognitive, affective) in long-term breast cancer survivors. METHOD Patients recruited between 2002 and 2005 provided information on CRF at first follow-up (FU1) (N = 1292) and second follow-up (FU2) (N = 1205), after a median of 6.2 years and 11.7 years, respectively. Associations of 11 inflammatory biomarkers with CRF at FU1 and at FU2 were assessed using linear regression models. Logistic regression models were used to compare patients fatigued at both time-points and those never fatigued (N = 932). RESULTS C-reactive protein (CRP) was significantly associated with total CRF at FU1 (β = 1.47, 95%CI = 0.62-2.31, p = 0.0007), at FU2 (β = 1.98, 95 %CI = 0.96-2.99, p = 0.0001) and with persistent CRF (OR = 1.29, 95%CI = 1.13-1.47, p < 0.0001). IL-6 levels were associated with total CRF at FU1 (β = 1.01, 95%CI = 0.43-1.59, p = 0.0006), but not with CRF at FU2 or persistent CRF. No association remained significant after adjustment for relevant covariates. DISCUSSION CRP and Il-6 were associated with risk of CRF in long-term breast cancer survivors, but were not independent of other known risk factors, suggesting that currently studied inflammatory markers are not suitable to identify patients at risk of long-term CRF.
Collapse
Affiliation(s)
- T Maurer
- Cancer Epidemiology, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg (UCCH), Hamburg, Germany
| | - S Jaskulski
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute for Prevention and Cancer Epidemiology, Faculty of Medicine and Medical Center, University Medical Center, University of Freiburg, Freiburg, Germany
| | - S Behrens
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - A Y Jung
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - N Obi
- Institute for Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - T Johnson
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - H Becher
- Institute for Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - J Chang-Claude
- Cancer Epidemiology, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg (UCCH), Hamburg, Germany; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
| |
Collapse
|
7
|
Zahn R, Hochadel M, Schumacher B, Pauschinger M, Stellbrink C, Schaechinger V, Behrens S, Mudra H, Elsaesser A, Zeymer U. Cardiogenic shock and radial access in patients with an acute ST elevation myocardial infarction. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1791] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Cardiogenic shock (CS) in patients (pts) with acute ST elevation myocardial infarction (STEMI) is the strongest predictor of hospital mortality. Radial in contrast to femoral access in STEMI pts might be associated with a lower mortality. However, little is known on radial access in CS pts.
Methods
We retrospectively analysed all STEMI pts between 2009 and 2015 who sufferend from CS and who were included into the ALKK PCI registry. Pts treated via a radial access were compared to those treated via a femoral access.
Results
Between 2009 and 2015 23796 STEMI pts were included in the registry. 1763 (7.4%) of pts were in CS. The proportion of radial access was 6.6%: in 2009 4.0% and in 2015 19.6%, p for trend <0.0001 with a strong variation between the participating centres (0% to 37%).
Conclusions
Radial access was only used in 6.6% of STEMI pts presenting in CS. However, a significant increase in the use of radial access was observed over time (2009: 4%, 2015 19.6%, p<0.001), with a great variance in its use between the participating hospitals. Despite similar pt characteristics the difference in hospital mortality according to access site has to be interpretated with caution.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- R Zahn
- Klinikum Ludwigshafen, Ludwigshafen, Germany
| | - M Hochadel
- Stiftung Institut, Ludwigshafen, Germany
| | | | - M Pauschinger
- klinikum Nuernberg - Sued-Nuernberg, Nuremberg, Germany
| | | | - V Schaechinger
- Klinikum Fulda Heart-Thorax-Center Cardiology, Fulda, Germany
| | - S Behrens
- Vivantes Humboldt Klinikum, Berlin, Germany
| | - H Mudra
- Clinic Neuperlach, Munich, Germany
| | | | - U Zeymer
- Klinikum Ludwigshafen, Ludwigshafen, Germany
| |
Collapse
|
8
|
Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, Leong HS, Chen S, Elatre W, Gilks B, Nazeran T, Volchek M, Bentley RC, Wang C, Chiu DS, Kommoss S, Leung SCY, Senz J, Lum A, Chow V, Sudderuddin H, Mackenzie R, George J, Fereday S, Hendley J, Traficante N, Steed H, Koziak JM, Köbel M, McNeish IA, Goranova T, Ennis D, Macintyre G, Silva De Silva D, Ramón Y Cajal T, García-Donas J, Hernando Polo S, Rodriguez GC, Cushing-Haugen KL, Harris HR, Greene CS, Zelaya RA, Behrens S, Fortner RT, Sinn P, Herpel E, Lester J, Lubiński J, Oszurek O, Tołoczko A, Cybulski C, Menkiszak J, Pearce CL, Pike MC, Tseng C, Alsop J, Rhenius V, Song H, Jimenez-Linan M, Piskorz AM, Gentry-Maharaj A, Karpinskyj C, Widschwendter M, Singh N, Kennedy CJ, Sharma R, Harnett PR, Gao B, Johnatty SE, Sayer R, Boros J, Winham SJ, Keeney GL, Kaufmann SH, Larson MC, Luk H, Hernandez BY, Thompson PJ, Wilkens LR, Carney ME, Trabert B, Lissowska J, Brinton L, Sherman ME, Bodelon C, Hinsley S, Lewsley LA, Glasspool R, Banerjee SN, Stronach EA, Haluska P, Ray-Coquard I, Mahner S, Winterhoff B, Slamon D, Levine DA, Kelemen LE, Benitez J, Chang-Claude J, Gronwald J, Wu AH, Menon U, Goodman MT, Schildkraut JM, Wentzensen N, Brown R, Berchuck A, Chenevix-Trench G, deFazio A, Gayther SA, García MJ, Henderson MJ, Rossing MA, Beeghly-Fadiel A, Fasching PA, Orsulic S, Karlan BY, Konecny GE, Huntsman DG, Bowtell DD, Brenton JD, Doherty JA, Pharoah PDP, Ramus SJ. Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol 2020; 31:1240-1250. [PMID: 32473302 PMCID: PMC7484370 DOI: 10.1016/j.annonc.2020.05.019] [Citation(s) in RCA: 72] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2020] [Revised: 05/06/2020] [Accepted: 05/06/2020] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic signature for OS in patients with HGSOC. PATIENTS AND METHODS Expression of 513 genes, selected from a meta-analysis of 1455 tumours and other candidates, was measured using NanoString technology from formalin-fixed paraffin-embedded tumour tissue collected from 3769 women with HGSOC from multiple studies. Elastic net regularization for survival analysis was applied to develop a prognostic model for 5-year OS, trained on 2702 tumours from 15 studies and evaluated on an independent set of 1067 tumours from six studies. RESULTS Expression levels of 276 genes were associated with OS (false discovery rate < 0.05) in covariate-adjusted single-gene analyses. The top five genes were TAP1, ZFHX4, CXCL9, FBN1 and PTGER3 (P < 0.001). The best performing prognostic signature included 101 genes enriched in pathways with treatment implications. Each gain of one standard deviation in the gene expression score conferred a greater than twofold increase in risk of death [hazard ratio (HR) 2.35, 95% confidence interval (CI) 2.02-2.71; P < 0.001]. Median survival [HR (95% CI)] by gene expression score quintile was 9.5 (8.3 to -), 5.4 (4.6-7.0), 3.8 (3.3-4.6), 3.2 (2.9-3.7) and 2.3 (2.1-2.6) years. CONCLUSION The OTTA-SPOT (Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovarian Tumours) gene expression signature may improve risk stratification in clinical trials by identifying patients who are least likely to achieve 5-year survival. The identified novel genes associated with the outcome may also yield opportunities for the development of targeted therapeutic approaches.
Collapse
Affiliation(s)
- J Millstein
- Division of Biostatistics, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - T Budden
- School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, Australia; CRUK Manchester Institute, The University of Manchester, Manchester, UK
| | - E L Goode
- Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, USA
| | - M S Anglesio
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada
| | - A Talhouk
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada
| | - M P Intermaggio
- School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, Australia
| | - H S Leong
- Peter MacCallum Cancer Center, Melbourne, Australia
| | - S Chen
- Center for Cancer Prevention and Translational Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA
| | - W Elatre
- Department of Pathology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, USA
| | - B Gilks
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
| | - T Nazeran
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada
| | - M Volchek
- Anatomical Pathology, Royal Women's Hospital, Parkville, Australia
| | - R C Bentley
- Department of Pathology, Duke University Hospital, Durham, USA
| | - C Wang
- Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, USA
| | - D S Chiu
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada
| | - S Kommoss
- Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany
| | - S C Y Leung
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada
| | - J Senz
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
| | - A Lum
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada
| | - V Chow
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada
| | - H Sudderuddin
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada
| | - R Mackenzie
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada
| | - J George
- The Jackson Laboratory for Genomic Medicine, Farmington, USA
| | - S Fereday
- Peter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia
| | - J Hendley
- Peter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia
| | - N Traficante
- Peter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia
| | - H Steed
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Royal Alexandra Hospital, Edmonton, Canada
| | - J M Koziak
- Alberta Health Services-Cancer Care, Calgary, Canada
| | - M Köbel
- Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Canada
| | - I A McNeish
- Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, Imperial College London, London, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - T Goranova
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - D Ennis
- Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, Imperial College London, London, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - G Macintyre
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - D Silva De Silva
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - T Ramón Y Cajal
- Medical Oncology Service, Hospital Sant Pau, Barcelona, Spain
| | - J García-Donas
- HM Hospitales D Centro Integral Oncológico HM Clara Campal, Madrid, Spain
| | - S Hernando Polo
- Medical Oncology Service, Hospital Universitario Funcacion Alcorcon, Alcorcón, Spain
| | - G C Rodriguez
- Division of Gynecologic Oncology, NorthShore University HealthSystem, University of Chicago, Evanston, USA
| | - K L Cushing-Haugen
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, USA
| | - H R Harris
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, USA; Department of Epidemiology, University of Washington, Seattle, USA
| | - C S Greene
- Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
| | - R A Zelaya
- Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, USA
| | - S Behrens
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - R T Fortner
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - P Sinn
- Department of Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
| | - E Herpel
- Department of Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
| | - J Lester
- David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, USA; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA
| | - J Lubiński
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - O Oszurek
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - A Tołoczko
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - C Cybulski
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - J Menkiszak
- Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland
| | - C L Pearce
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, USA; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA
| | - M C Pike
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA; Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - C Tseng
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - J Alsop
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - V Rhenius
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - H Song
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - M Jimenez-Linan
- Department of Pathology, Addenbrooke's Hospital NHS Trust, Cambridge, UK
| | - A M Piskorz
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - A Gentry-Maharaj
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK
| | - C Karpinskyj
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK
| | - M Widschwendter
- Department of Women's Cancer, Institute for Women's Health, University College London, London, UK
| | - N Singh
- Department of Pathology, Barts Health National Health Service Trust, London, UK
| | - C J Kennedy
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia
| | - R Sharma
- Pathology West ICPMR Westmead, Westmead Hospital, The University of Sydney, Sydney, Australia; University of Western Sydney at Westmead Hospital, Sydney, Australia
| | - P R Harnett
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; The Crown Princess Mary Cancer Centre Westmead, Sydney-West Cancer Network, Westmead Hospital, Sydney, Australia
| | - B Gao
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; The Crown Princess Mary Cancer Centre Westmead, Sydney-West Cancer Network, Westmead Hospital, Sydney, Australia
| | - S E Johnatty
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - R Sayer
- Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia
| | - J Boros
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia
| | - S J Winham
- Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, USA
| | - G L Keeney
- Department of Laboratory Medicine and Pathology, Division of Anatomic Pathology, Mayo Clinic, Rochester, USA
| | - S H Kaufmann
- Department of Oncology, Mayo Clinic, Rochester, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA
| | - M C Larson
- Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, USA
| | - H Luk
- Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, USA
| | - B Y Hernandez
- Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, USA
| | - P J Thompson
- Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, USA
| | - L R Wilkens
- Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, USA
| | - M E Carney
- John A. Burns School of Medicine, Department of Obstetrics and Gynecology, University of Hawaii, Honolulu, USA
| | - B Trabert
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA
| | - J Lissowska
- Department of Cancer Epidemiology and Prevention, M Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland
| | - L Brinton
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA
| | - M E Sherman
- Department of Health Sciences Research, Mayo Clinic College of Medicine, Jacksonville, USA
| | - C Bodelon
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA
| | - S Hinsley
- Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - L A Lewsley
- Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - R Glasspool
- Department of Medical Oncology, Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, UK
| | - S N Banerjee
- The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
| | - E A Stronach
- Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, Imperial College London, London, UK
| | - P Haluska
- Department of Oncology, Mayo Clinic, Rochester, USA
| | - I Ray-Coquard
- Centre Leon Berard and University Claude Bernard Lyon 1, Lyon, France
| | - S Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - B Winterhoff
- Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, USA
| | - D Slamon
- David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, USA
| | - D A Levine
- Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA; Gynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center, NYU Langone Medical Center, New York, USA
| | - L E Kelemen
- Hollings Cancer Center and Department of Public Health Sciences, Medical University of South Carolina, Charleston, USA
| | - J Benitez
- Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain; Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - J Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - J Gronwald
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - A H Wu
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - U Menon
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK
| | - M T Goodman
- Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, USA
| | - J M Schildkraut
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, USA
| | - N Wentzensen
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA
| | - R Brown
- Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK
| | - A Berchuck
- Department of Gynecologic Oncology, Duke University Hospital, Durham, USA
| | - G Chenevix-Trench
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - A deFazio
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia
| | - S A Gayther
- Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, USA
| | - M J García
- Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain
| | - M J Henderson
- Children's Cancer Institute, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, Australia
| | - M A Rossing
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, USA; Department of Epidemiology, University of Washington, Seattle, USA
| | - A Beeghly-Fadiel
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, USA
| | - P A Fasching
- David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, USA; Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
| | - S Orsulic
- David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, USA; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA
| | - B Y Karlan
- David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, USA; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA
| | - G E Konecny
- David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, USA
| | - D G Huntsman
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, Canada
| | - D D Bowtell
- Peter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia
| | - J D Brenton
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - J A Doherty
- Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, USA
| | - P D P Pharoah
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - S J Ramus
- School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, Australia; Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, Australia.
| |
Collapse
|
9
|
Veldwijk M, Seibold P, Helmbold I, Sperk E, Giordano F, Behrens S, Wenz F, Chang-Claude J, Herskind C. Prediction of Radiation-induced Breast Fibrosis by the Radiation-induced Lymphocyte Apoptosis Assay: Relation to the Surgical Area. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Kühl T, Behrens S, Jung AY, Obi N, Thöne K, Schmidt ME, Becher H, Chang-Claude J. Validation of inflammatory genetic variants associated with long-term cancer related fatigue in a large breast cancer cohort. Brain Behav Immun 2018; 73:252-260. [PMID: 29763737 DOI: 10.1016/j.bbi.2018.05.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Revised: 05/02/2018] [Accepted: 05/09/2018] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Studies to date have reported several associations between single nucleotide polymorphisms (SNPs) and cancer related fatigue (CRF), but have been limited by small sample sizes, missing adjustment for relevant covariates or multiple testing, as well as varying CRF definitions, i.e. time and method of assessment. This study aimed to validate previously reported associations using the largest independent breast cancer sample to date and to evaluate further functional cytokine variants in relation to total CRF and all relevant CRF subdomains (physical, cognitive, and affective CRF). METHOD 45 candidate SNPs in inflammatory pathway genes were selected based on previous reports (16 SNPs) or regulatory function (29 SNPs). Breast cancer patients recruited between 2002 and 2005 provided information on CRF at first follow-up (FU1) (N = 1389) and second follow-up (FU2) (N = 950), a median of 6.2 years and 11.7 years respectively after diagnosis. SNP associations were assessed using linear regression models on CRF scores separately for FU1 and FU2. Additionally, patients with persistent fatigue (fatigued at both time-points) were compared to those never fatigued using logistic regression models (N = 684). All analyses were adjusted for relevant covariates. Secondary analyses were conducted for CRF subdomains. RESULTS For total CRF none of the previously reported associations were confirmed after correction for multiple testing. The p-value distribution of all SNPs was not different than the one expected by chance. Analyses of CRF subdomains yielded a significant association between TNF-α rs3093662 and persistent physical CRF (Odds Ratio (OR) = 3.23, 95% Confidence Interval (CI) = 1.71-6.10, p = 0.0003). CONCLUSION We were unable to confirm previously reported findings, suggesting that individual SNPs are unlikely to be of clinical utility. Further investigations in well powered studies are warranted, which consider genetic heterogeneity according to subdomains of CRF.
Collapse
Affiliation(s)
- T Kühl
- Cancer Epidemiology, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S Behrens
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - A Y Jung
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - N Obi
- Institute for Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - K Thöne
- Cancer Epidemiology, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M E Schmidt
- Division of Physical Activity, Prevention and Cancer, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - H Becher
- Institute for Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - J Chang-Claude
- Cancer Epidemiology, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
| |
Collapse
|
11
|
Stockburger M, Maier B, Behrens S, Bruch L, Butter C, Minden H, Schoeller R, Schuehlen H, Theres H. P5544Hospital admissions and mortality from myocardial infarction in Berlin and surrounding Brandenburg State. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Stockburger
- Havelland Kliniken, Academic Teaching Hospital, Cardiology, Nauen, Germany
| | - B Maier
- Berlin-Brandenburg Myocardial Infarction Registry (B2HIR), Berlin, Germany
| | - S Behrens
- Vivantes Humboldt Klinikum, Berlin, Germany
| | - L Bruch
- UKB Berlin, Cardiology, Berlin, Germany
| | - C Butter
- Brandenburg Heart Center, Cardiology, Bernau bei Berlin, Germany
| | - H Minden
- Oberhavel Kliniken, Cardiology, Hennigsdorf, Germany
| | - R Schoeller
- Berlin-Brandenburg Myocardial Infarction Registry (B2HIR), Berlin, Germany
| | - H Schuehlen
- Vivantes Auguste-Viktoria Klinikum, Cardiology, Berlin, Germany
| | - H Theres
- Charite - Campus Mitte (CCM), Cardiology and Angiology, Berlin, Germany
| | | |
Collapse
|
12
|
Kühl T, Behrens S, Jung A, Thöne K, Chang-Claude J. Cytokine gene variants associated with persistent cancer related fatigue in breast cancer patients. Das Gesundheitswesen 2017. [DOI: 10.1055/s-0037-1606025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- T Kühl
- University Medical Center Hamburg-Eppendorf/University Cancer Center Hamburg, Genetic Tumour Epidemiology, Hamburg
| | - S Behrens
- German Cancer Research Center (DKFZ), Cancer Epidemiology, Heidelberg
| | - A Jung
- German Cancer Research Center (DKFZ), Cancer Epidemiology, Heidelberg
| | - K Thöne
- University Medical Center Hamburg-Eppendorf/University Cancer Center Hamburg, Cancer Epidemiology/Clinical Cancer Registry, Hamburg
| | - J Chang-Claude
- University Medical Center Hamburg-Eppendorf/University Cancer Center Hamburg, Genetic Tumour Epidemiology, Hamburg
- German Cancer Research Center (DKFZ), Cancer Epidemiology, Heidelberg
| |
Collapse
|
13
|
Roehnisch JU, Maier B, Behrens S, Schoeller R, Schuehlen H, Theres H. P5537Development of antithrombotic therapy and bleeding complications in patients with ACS over time: Data from a local myocardial infarction registry. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - B. Maier
- Berlin Myocardial Infarction Registry at TU Berlin, Berlin, Germany
| | - S. Behrens
- Vivantes Humboldt-Klinikum, Berlin, Germany
| | | | - H. Schuehlen
- Vivantes Auguste-Viktoria Hospital, Berlin, Germany
| | - H. Theres
- Charite - University Medicine Berlin, Campus Mitte, Berlin, Germany
| | | |
Collapse
|
14
|
Laag V, Maier B, Behrens S, Schoeller R, Schuehlen H, Theres H, Doehner W. P4632Impact of body mass index on hospital mortality in acute myocardial infarction over 15 years: Findings from 27,607 patients of a local myocardial infarction registry. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p4632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- V. Laag
- Berlin Myocardial Infarction Registry at TU Berlin, Berlin, Germany
| | - B. Maier
- Berlin Myocardial Infarction Registry at TU Berlin, Berlin, Germany
| | - S. Behrens
- Vivantes Humboldt Klinikum, Berlin, Germany
| | | | - H. Schuehlen
- Vivantes Auguste-Viktoria Klinikum, Berlin, Germany
| | - H. Theres
- Charite - Campus Mitte (CCM), Berlin, Germany
| | - W. Doehner
- Charite - Campus Virchow-Klinikum (CVK), Berlin, Germany
| | | |
Collapse
|
15
|
Jung A, Behrens S, Eilber U, Thoene K, Hüsing A, Chang-Claude J. Post-diagnostic weight change and all-cause mortality of postmenopausal breast cancer patients. Das Gesundheitswesen 2017. [DOI: 10.1055/s-0037-1605870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- A Jung
- German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg
| | - S Behrens
- German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg
| | - U Eilber
- German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg
| | - K Thoene
- University Medical Center Hamburg-Eppendorf (UKE), Hamburg
| | - A Hüsing
- German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg
| | - J Chang-Claude
- German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg
- University Medical Center Hamburg-Eppendorf (UKE), Hamburg
| |
Collapse
|
16
|
Obi N, zu Eulenburg C, Seibold P, Eilber U, Thöne K, Behrens S, Chang-Claude J, Flesch-Janys D. Associations between radiotherapy and causes of death as potential late side effects in a German breast cancer cohort. Das Gesundheitswesen 2017. [DOI: 10.1055/s-0037-1605840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- N Obi
- Universitätsklinikum Hamburg-Eppendorf, Inst. f. Medizinische Biometrie & Epidemiologie, Hamburg
| | - C zu Eulenburg
- Universitätsklinikum Hamburg-Eppendorf, Inst. f. Medizinische Biometrie & Epidemiologie, Hamburg
- University of Groningen, Medical Statistics and Decision Making, Groningen
| | - P Seibold
- German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg
| | - U Eilber
- German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg
| | - K Thöne
- University Medical Center Hamburg-Eppendorf, Department of Cancer Epidemiology/Clinical Cancer Registry, Hamburg
| | - S Behrens
- German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg
| | - J Chang-Claude
- German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg
- University Medical Center Hamburg-Eppendorf, Genetic Tumor Epidemiology Group, Hamburg
| | - D Flesch-Janys
- Universitätsklinikum Hamburg-Eppendorf, Inst. f. Medizinische Biometrie & Epidemiologie, Hamburg
- University Medical Center Hamburg-Eppendorf, Department of Cancer Epidemiology/Clinical Cancer Registry, Hamburg
| |
Collapse
|
17
|
Vernon E, Cooley B, Rozum W, Rattinger G, Behrens S, Tschanz J. CAREGIVER-CARE RECIPIENT RELATIONSHIPS ARE ASSOCIATED WITH NEUROPSYCHIATRIC SYMPTOMS IN DEMENTIA. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.2011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | | | - W. Rozum
- Utah State University, Logan, Utah,
| | | | | | | |
Collapse
|
18
|
Behrens S, Gail R, De Berard S, Schwartz S, Matyi J, Sanders C, Tschanz J. ANTIDEMENTIA MEDICATION USE IS ASSOCIATED WITH DECREASED INFORMAL COSTS IN MILD DEMENTIA. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.3228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - R.B. Gail
- Binghamton University, Binghamton, New York
| | | | | | - J. Matyi
- Utah State University, Logan, Utah,
| | | | | |
Collapse
|
19
|
Llevot A, Monney B, Sehlinger A, Behrens S, Meier MAR. Highly efficient Tsuji–Trost allylation in water catalyzed by Pd-nanoparticles. Chem Commun (Camb) 2017; 53:5175-5178. [DOI: 10.1039/c7cc02380d] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Palladium nanoparticles stabilized by poly(vinylpyrrolidone) catalyze Tsuji–Trost allylations in water with very high turnover numbers.
Collapse
Affiliation(s)
- A. Llevot
- Karlsruhe Institute of Technology (KIT)
- Institute of Organic Chemistry (IOC)
- Materialwissenschaftliches Zentrum MZE
- 76131 Karlsruhe
- Germany
| | - B. Monney
- Karlsruhe Institute of Technology (KIT)
- Institute of Organic Chemistry (IOC)
- Materialwissenschaftliches Zentrum MZE
- 76131 Karlsruhe
- Germany
| | - A. Sehlinger
- Karlsruhe Institute of Technology (KIT)
- Institute of Organic Chemistry (IOC)
- Materialwissenschaftliches Zentrum MZE
- 76131 Karlsruhe
- Germany
| | - S. Behrens
- Institut für Katalyseforschung und -technologie (IKFT)
- Karlsruher Institut für Technologie (KIT)
- 76021 Karlsruhe
- Germany
| | - M. A. R. Meier
- Karlsruhe Institute of Technology (KIT)
- Institute of Organic Chemistry (IOC)
- Materialwissenschaftliches Zentrum MZE
- 76131 Karlsruhe
- Germany
| |
Collapse
|
20
|
Veldwijk M, Botma A, Helmbold I, Gürth N, Kirchner A, Behrens S, Seibold P, Wenz F, Chang-Claude J, Herskind C. Association of T lymphocyte Apoptosis after In Vitro Irradiation with Normal Tissue Late Toxicity after Radiation Therapy in 252 Breast Cancer Patients with 10-Year Clinical Follow-up. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
21
|
Ruecker A, Schröder C, Byrne J, Weigold P, Behrens S, Kappler A. Geochemistry and Mineralogy of Western Australian Salt Lake Sediments: Implications for Meridiani Planum on Mars. Astrobiology 2016; 16:525-538. [PMID: 27258848 DOI: 10.1089/ast.2015.1429] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
UNLABELLED Hypersaline lakes are characteristic for Western Australia and display a rare combination of geochemical and mineralogical properties that make these lakes potential analogues for past conditions on Mars. In our study, we focused on the geochemistry and mineralogy of Lake Orr and Lake Whurr. While both lakes are poor in organic carbon (<1%), the sediments' pH values differ and range from 3.8 to 4.8 in Lake Orr and from 5.4 to 6.3 in Lake Whurr sediments. Lake Whurr sediments were dominated by orange and red sediment zones in which the main Fe minerals were identified as hematite, goethite, and tentatively jarosite and pyrite. Lake Orr was dominated by brownish and blackish sediments where the main Fe minerals were goethite and another paramagnetic Fe(III)-phase that could not be identified. Furthermore, a likely secondary Fe(II)-phase was observed in Lake Orr sediments. The mineralogy of these two salt lakes in the sampling area is strongly influenced by events such as flooding, evaporation, and desiccation, processes that explain at least to some extent the observed differences between Lake Orr and Lake Whurr. The iron mineralogy of Lake Whurr sediments and the high salinity make this lake a suitable analogue for Meridiani Planum on Mars, and in particular the tentative identification of pyrite in Lake Whurr sediments has implications for the interpretation of the Fe mineralogy of Meridiani Planum sediments. KEY WORDS Western Australia-Salt lakes-Jarosite-Hematite-Pyrite-Mars analogue. Astrobiology 16, 525-538.
Collapse
Affiliation(s)
- A Ruecker
- 1 Geomicrobiology, Center for Applied Geosciences, University of Tübingen , Tübingen, Germany
| | - C Schröder
- 2 Biological and Environmental Sciences, School of Natural Sciences, University of Stirling , Stirling, Scotland, UK
| | - J Byrne
- 1 Geomicrobiology, Center for Applied Geosciences, University of Tübingen , Tübingen, Germany
| | - P Weigold
- 1 Geomicrobiology, Center for Applied Geosciences, University of Tübingen , Tübingen, Germany
| | - S Behrens
- 1 Geomicrobiology, Center for Applied Geosciences, University of Tübingen , Tübingen, Germany
| | - A Kappler
- 1 Geomicrobiology, Center for Applied Geosciences, University of Tübingen , Tübingen, Germany
| |
Collapse
|
22
|
Gentzen M, Habicht W, Doronkin DE, Grunwaldt JD, Sauer J, Behrens S. Bifunctional hybrid catalysts derived from Cu/Zn-based nanoparticles for single-step dimethyl ether synthesis. Catal Sci Technol 2016. [DOI: 10.1039/c5cy01043h] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Model kit for bifunctional catalysts: colloidal Cu/Zn-based nanoparticles were synthesized and used as building blocks in syngas to dimethyl ether (STD) catalysts.
Collapse
Affiliation(s)
- M. Gentzen
- Institute of Catalysis Research and Technology
- Karlsruhe Institute of Technology (KIT)
- Germany
| | - W. Habicht
- Institute of Catalysis Research and Technology
- Karlsruhe Institute of Technology (KIT)
- Germany
| | - D. E. Doronkin
- Institute of Catalysis Research and Technology
- Karlsruhe Institute of Technology (KIT)
- Germany
- Institute for Chemical Technology and Polymer Chemistry
- Karlsruhe Institute of Technology (KIT)
| | - J.-D. Grunwaldt
- Institute of Catalysis Research and Technology
- Karlsruhe Institute of Technology (KIT)
- Germany
- Institute for Chemical Technology and Polymer Chemistry
- Karlsruhe Institute of Technology (KIT)
| | - J. Sauer
- Institute of Catalysis Research and Technology
- Karlsruhe Institute of Technology (KIT)
- Germany
| | - S. Behrens
- Institute of Catalysis Research and Technology
- Karlsruhe Institute of Technology (KIT)
- Germany
| |
Collapse
|
23
|
Weigold P, Ruecker A, Jochmann M, Osorio Barajas XL, Lege S, Zwiener C, Kappler A, Behrens S. Formation of chloroform and tetrachloroethene by Sinorhizobium meliloti strain 1021. Lett Appl Microbiol 2015; 61:346-53. [PMID: 26119060 DOI: 10.1111/lam.12462] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2015] [Revised: 06/08/2015] [Accepted: 06/22/2015] [Indexed: 12/16/2022]
Abstract
UNLABELLED The mechanisms and organisms involved in the natural formation of volatile organohalogen compounds (VOX) are largely unknown. We provide evidence that the common and widespread soil bacterium Sinorhizobium meliloti strain 1021 is capable of producing up to 3338·6 ± 327·8 ng l(-1) headspace volume of chloroform (CHCl3 ) and 807·8 ± 13·5 ng l(-1) headspace volume of tetrachloroethene (C2 Cl4 ) within 1 h when grown in soil extract medium. Biotic VOX formation has been suggested to be linked to the activity of halogenating enzymes such as haloperoxidases. We tested if the observed VOX formation by S. meliloti can be attributed to one of its chloroperoxidases (Smc01944) that is highly expressed in the presence of H2 O2. However, addition of 10 mmol l(-1) H2 O2 to the S. meliloti cultures decreased VOX formation by 52% for chloroform and 25% for tetrachloroethene, while viable cell numbers decreased by 23%. Interestingly, smc01944 gene expression increased 450-fold. The quantification of extracellular chlorination activity in cell suspension experiments did not provide evidence for a role of S. meliloti chloroperoxidases in the observed VOX formation. This suggests that a momentarily unknown mechanism which requires no H2 O2 might be responsible for the VOX formation by S. meliloti. Regardless of the underlying mechanism our results suggest that the soil bacterium S. meliloti might be an important source of VOX in soils. SIGNIFICANCE AND IMPACT OF THE STUDY Volatile organohalogen compounds (VOX) strongly influence atmospheric chemistry and Earth's climate. Besides anthropogenic emissions they are naturally produced by either abiotic or biotic pathways in various environments. Particularly in soils, microbial processes drive the natural halogen cycle but the direct link to microbial VOX formation has not been studied in detail yet. In this study we provide evidence that the common and widespread soil bacterium Sinorhizobium meliloti strain 1021 forms chloroform and tetrachloroethene. The potential contribution of S. meliloti to soil VOX release could significantly influence soil and atmospheric chemistry.
Collapse
Affiliation(s)
- P Weigold
- Geomicrobiology, Center for Applied Geosciences, University of Tuebingen, Tuebingen, Germany
| | - A Ruecker
- Geomicrobiology, Center for Applied Geosciences, University of Tuebingen, Tuebingen, Germany
| | - M Jochmann
- Instrumental Analytical Chemistry, Faculty of Chemistry, University of Duisburg-Essen, Essen, Germany
| | - X L Osorio Barajas
- Instrumental Analytical Chemistry, Faculty of Chemistry, University of Duisburg-Essen, Essen, Germany
| | - S Lege
- Environmental Analytical Chemistry, Center for Applied Geosciences, University of Tuebingen, Tuebingen, Germany
| | - C Zwiener
- Environmental Analytical Chemistry, Center for Applied Geosciences, University of Tuebingen, Tuebingen, Germany
| | - A Kappler
- Geomicrobiology, Center for Applied Geosciences, University of Tuebingen, Tuebingen, Germany
| | - S Behrens
- Geomicrobiology, Center for Applied Geosciences, University of Tuebingen, Tuebingen, Germany.,Department of Civil, Environmental, and Geo-Engineering, University of Minnesota, Minneapolis, MN, USA.,BioTechnology Institute, University of Minnesota, Minneapolis, MN, USA
| |
Collapse
|
24
|
Maier B, Wagner K, Behrens S, Bruch L, Busse R, Schmidt D, Schühlen H, Thieme R, Theres H. [Deterministic record linkage with indirect identifiers: data of the Berlin Myocardial Infarction Registry and the AOK Nordost for patients with myocardial infarction]. Gesundheitswesen 2015; 77:e15-9. [PMID: 25714193 DOI: 10.1055/s-0034-1395642] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
AIM OF THE STUDY How can 2 pseudonymised data sets be linked? Using the example of data from the Berlin Myocardial Infarction Registry and from a German sickness fund (AOK Nordost) we will demonstrate how record linkage can be achieved without personal identifiers. METHODS In different steps the method of deterministic record linkage with indirect identifiers: age, sex, hospital admission date and time, will be explained. RESULTS We were able to show that 80.6% of the expected maximum number of patients were matched with our approach. As a result we had no duplicate matches in the linkage process, where one AOK patient was linked to 2 or more BMIR patients or vice versa. The matching variables produced enough uniqueness to be used as indirect patient identifiers. CONCLUSION Deterministic record linkage with the following indirect indicators: age, sex, hospital admission date and time was possible in our study of patients with myocardial infarction in a circumscribed geographical region, which limited the number of cases and avoided mismatches.
Collapse
Affiliation(s)
- B Maier
- Berliner Herzinfarktregister am Fachgebiet Management im Gesundheitswesen an TU Berlin
| | - K Wagner
- Berliner Herzinfarktregister am Fachgebiet Management im Gesundheitswesen an TU Berlin
| | - S Behrens
- Kardiologie, Vivantes Humboldt-Klinikum, Berlin
| | - L Bruch
- Kardiologie, Unfallkrankenhaus Berlin, Berlin
| | - R Busse
- Management im Gesundheitswesen, TU Berlin, Berlin
| | - D Schmidt
- Krankenhausplanung, AOK Nordost, Berlin
| | - H Schühlen
- Kardiologie, Vivantes Auguste-Viktoria-Klinikum, Berlin
| | - R Thieme
- Kardiologie, Jüdisches Krankenhaus Berlin, Berlin
| | - H Theres
- Kardiologie, Humboldtmühle Medical Park, Berlin
| |
Collapse
|
25
|
Ruecker A, Weigold P, Behrens S, Jochmann M, Laaks J, Kappler A. Predominance of biotic over abiotic formation of halogenated hydrocarbons in hypersaline sediments in Western Australia. Environ Sci Technol 2014; 48:9170-9178. [PMID: 25073729 DOI: 10.1021/es501810g] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Volatile halogenated organic compounds (VOX) contribute to ozone depletion and global warming. There is evidence of natural VOX formation in many environments ranging from forest soils to salt lakes. Laboratory studies have suggested that VOX formation can be chemically stimulated by reactive Fe species while field studies have provided evidence for direct biological (enzymatic) VOX formation. However, the relative contribution of abiotic and biotic processes to global VOX budgets is still unclear. The goals of this study were to quantify VOX release from sediments from a hypersaline lake in Western Australia (Lake Strawbridge) and to distinguish between the relative contributions of biotic and abiotic VOX formation in microbially active and sterilized microcosms. Our experiments demonstrated that the release of organochlorines from Lake Strawbridge sediments was mainly biotic. Among the organochlorines detected were monochlorinated, e.g., chloromethane (CH3Cl), and higher chlorinated VOX compounds such as trichloromethane (CHCl3). Amendment of sediments with either Fe(III) oxyhydroxide (ferrihydrite) or a mixture of lactate/acetate or both ferrihydrite and lactate/acetate did not stimulate VOX formation. This suggests that although microbial Fe(III) reduction took place, there was no stimulation of VOX formation via Fe redox transformations or the formation of reactive Fe species under our experimental conditions.
Collapse
Affiliation(s)
- A Ruecker
- Geomicrobiology, Center for Applied Geosciences, University of Tübingen , Tübingen 72074, Germany
| | | | | | | | | | | |
Collapse
|
26
|
|
27
|
Roehnisch JU, Behrens S, Maier B, Schoeller R, Schuehlen H, Theres H. Changes in hospital care of octogenarians with acute coronary syndrome: data of the Berlin Myocardial Infarction Registry (BMIR). Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht309.p4049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Liosis S, Hochadel M, Darius H, Behrens S, Mudra H, Lauer B, Gitt AK, Zeymer U. The high event rate in patients with diabetes mellitus treated with PCI for acute coronary syndromes is observed in the subgroup of patients with impaired renal function. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht309.p3136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Schuehlen H, Maier B, Behrens S, Schoeller R, Theres H. Determinants of Door-to-balloon time in STEMI Patients: data from the Berlin Myocardial Infarction Registry (BMIR). Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht310.p5315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Rittger H, Hochadel M, Behrens S, Hauptmann KE, Zahn R, Mudra H, Brachmann J, Zeymer U. Interventional treatment and outcome in elderly patients with stable coronary artery disease. Results from the German ALKK registry. Herz 2013; 39:212-8. [PMID: 23712825 DOI: 10.1007/s00059-013-3822-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2012] [Revised: 03/07/2013] [Accepted: 03/24/2013] [Indexed: 12/13/2022]
Abstract
BACKGROUND The number of elderly and very elderly patients undergoing percutaneous coronary interventions (PCI) is increasing. We therefore analyzed data from the German ALKK registry (Arbeitsgemeinschaft Leitende Krankenhausärzte; Working Group of Hospital Cardiologists) to determine differences in procedural features, antithrombotic treatment, and in-hospital outcome in patients with coronary artery disease (CAD) according to age in a large series of patients. METHODS AND RESULTS The present analysis was based on the data of 35,534 consecutive patients undergoing elective PCI who were enrolled in the ALKK registry. Of these 27,145 (76.4 %) were younger than 75 years, 7,645 (21.5 %) were aged between 75 and 84 years, and 744 (2.1 %) patients were older than 85 years. Mean age was 68.5 years (60.9-74.5 years), and 25,784 patients (72.6 %) were male. Overall intraprocedural events were very low (1.1 %) and there was no significant difference between the three age groups [< 75 years (1.1 %); 75-< 85 years (1.2 %); ≥ 85 years (0.5 %) (p = not significant)]. Rates of in-hospital death, stroke and transient ischemic attack (TIA), as well as the combined endpoint in-hospital major adverse cardiac and cerebrovascular events (MACCE) were also very low (0.6 % vs. 0.9 % vs. 0.9 %; p < 0.001) but significantly higher in elderly patients with no further increase in the very elderly patient group. CONCLUSION We found no differences in this registry in intraprocedural complications during elective PCI between younger and elderly patients. Although in-hospital MACCE were somewhat higher in the elderly, the overall event rate was low and thus elderly patients should not be deprived from this therapy because of age alone.
Collapse
Affiliation(s)
- H Rittger
- Medizinische Klinik 2, Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany,
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Behrens S, Hegenbarth C, Maier B, Schoeller R, Schühlen H, Theres H. Wie beeinflussen Leitlinien die ärztliche Einschätzung von Risiken: Analyse am Beispiel der Behandlung von PatientInnen mit akutem Herzinfarkt und Vorhofflimmern aus Berlin. Dtsch Med Wochenschr 2012. [DOI: 10.1055/s-0032-1323185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
32
|
Röhnisch JU, Maier B, Behrens S, Schoeller R, Schühlen H, Theres H. Diabetes mellitus und Niereninsuffizienz bei PatientInnen mit Herzinfarkt: 5-Jahresdaten des Berliner Herzinfarktregisters. Dtsch Med Wochenschr 2012. [DOI: 10.1055/s-0032-1323443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
33
|
Theres H, Behrens S, Schoeller R, Schühlen H, Maier B. Determinanten der Door-to-balloon Zeit von PatientInnen mit akutem Herzinfarkt: Daten des Berliner Herzinfarktregisters (BHIR). Dtsch Med Wochenschr 2012. [DOI: 10.1055/s-0032-1323497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
34
|
Bucsenez M, Rüping B, Behrens S, Twyman RM, Noll GA, Prüfer D. Multiple cis-regulatory elements are involved in the complex regulation of the sieve element-specific MtSEO-F1 promoter from Medicago truncatula. Plant Biol (Stuttg) 2012; 14:714-24. [PMID: 22404711 DOI: 10.1111/j.1438-8677.2011.00556.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
The sieve element occlusion (SEO) gene family includes several members that are expressed specifically in immature sieve elements (SEs) in the developing phloem of dicotyledonous plants. To determine how this restricted expression profile is achieved, we analysed the SE-specific Medicago truncatula SEO-F1 promoter (PMtSEO-F1) by constructing deletion, substitution and hybrid constructs and testing them in transgenic tobacco plants using green fluorescent protein as a reporter. This revealed four promoter regions, each containing cis-regulatory elements that activate transcription in SEs. One of these segments also contained sufficient information to suppress PMtSEO-F1 transcription in the phloem companion cells (CCs). Subsequent in silico analysis revealed several candidate cis-regulatory elements that PMtSEO-F1 shares with other SEO promoters. These putative sieve element boxes (PSE boxes) are promising candidates for cis-regulatory elements controlling the SE-specific expression of PMtSEO-F1.
Collapse
Affiliation(s)
- M Bucsenez
- Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Aachen, Germany Institut für Biologie und Biotechnologie der Pflanzen, Westfälische Wilhelms-Universität Münster, Münster, Germany Max Planck Institute for Molecular Genetics, Computational Molecular Biology, Berlin, Germany Department of Biological Sciences, University of Warwick, Coventry, UK
| | - B Rüping
- Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Aachen, Germany Institut für Biologie und Biotechnologie der Pflanzen, Westfälische Wilhelms-Universität Münster, Münster, Germany Max Planck Institute for Molecular Genetics, Computational Molecular Biology, Berlin, Germany Department of Biological Sciences, University of Warwick, Coventry, UK
| | - S Behrens
- Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Aachen, Germany Institut für Biologie und Biotechnologie der Pflanzen, Westfälische Wilhelms-Universität Münster, Münster, Germany Max Planck Institute for Molecular Genetics, Computational Molecular Biology, Berlin, Germany Department of Biological Sciences, University of Warwick, Coventry, UK
| | - R M Twyman
- Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Aachen, Germany Institut für Biologie und Biotechnologie der Pflanzen, Westfälische Wilhelms-Universität Münster, Münster, Germany Max Planck Institute for Molecular Genetics, Computational Molecular Biology, Berlin, Germany Department of Biological Sciences, University of Warwick, Coventry, UK
| | - G A Noll
- Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Aachen, Germany Institut für Biologie und Biotechnologie der Pflanzen, Westfälische Wilhelms-Universität Münster, Münster, Germany Max Planck Institute for Molecular Genetics, Computational Molecular Biology, Berlin, Germany Department of Biological Sciences, University of Warwick, Coventry, UK
| | - D Prüfer
- Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Aachen, Germany Institut für Biologie und Biotechnologie der Pflanzen, Westfälische Wilhelms-Universität Münster, Münster, Germany Max Planck Institute for Molecular Genetics, Computational Molecular Biology, Berlin, Germany Department of Biological Sciences, University of Warwick, Coventry, UK
| |
Collapse
|
35
|
Ebbinghaus J, Maier B, Schoeller R, Schühlen H, Theres H, Behrens S. Früh-invasive Behandlungsstrategie und Krankenhausmortalität bei Frauen mit NSTEMI (Non-ST-Elevation Myocardial Infarction) – Daten aus dem Berliner Herzinfarktregister (BHIR). Gesundheitswesen 2010. [DOI: 10.1055/s-0030-1266223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
36
|
Butterbach K, Behrens S, de Sanjosé S, Benavente Y, Becker N, Foretova L, Maynadie M, Cocco P, Staines A, Boffetta P, Brennan P, Nieters A. Association of JAK-STAT pathway related genes with lymphoma risk. Gesundheitswesen 2010. [DOI: 10.1055/s-0030-1266455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
37
|
Maier B, Behrens S, Busse R, Sitsch A, Schmidt D, Schoeller R, Schühlen H, Theres H. Vergleich der Qualität der stationären Versorgung von Herzinfarktpatienten in Berlin auf der Basis von Routinedaten (AOK Berlin) und Daten des Berliner Herzinfarktregisters (BHIR). Gesundheitswesen 2010. [DOI: 10.1055/s-0030-1266507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
38
|
Röhnisch J, Glaser C, Behrens S, Maier B, Schühlen H, Schöller R, Theres H. 10 years of data collected in the Berlin Myocardial Infarction Registry (BMIR) – Changes in treatment and outcome for patients with acute myocardial infarction. Gesundheitswesen 2010. [DOI: 10.1055/s-0030-1266640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
39
|
Maier B, Behrens S, Busse R, Jonitz G, Schoeller R, Schuehlen H, Theres H. Überlegungen zu Validität und Vergleichbarkeit von Daten der Todesursachenstatistik, GKV Daten und Registerdaten am Beispiel Herzinfarkt. Gesundheitswesen 2009. [DOI: 10.1055/s-0029-1239099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
40
|
Behrens S, Ehlers C, Brüggemann T, Ziss W, Dissmann R, Galecka M, Willich SN, Andresen D. Modification of the circadian pattern of ventricular tachyarrhythmias by beta-blocker therapy. Clin Cardiol 2009; 20:253-7. [PMID: 9068912 PMCID: PMC6655728 DOI: 10.1002/clc.4960200313] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
BACKGROUND Sudden cardiac death exhibits a circadian variation and predominantly occurs during morning hours, Beta-adrenergic antagonists have shown to blunt this morning peak. However, previous reports studying the effects of beta blockers on the circadian variation did not analyze the underlying cause of sudden cardiac death. It thus remains unclear whether ventricular tachyarrhythmias are influenced by beta-blocker therapy. HYPOTHESIS This study tested the hypothesis that beta-blocking agents blunt the morning peak of life-threatening ventricular tachyarrhythmias. METHODS In 87 patients who were treated and monitored with an implantable cardioverter defibrillator, the circadian distribution of ventricular tachyarrhythmias terminated by appropriate shocks was analyzed and compared in those receiving beta blockers versus those not receiving beta-blocker therapy. RESULTS Tachyarrhythmic episodes in the absence of beta-blocker therapy (n = 344) exhibited a circadian variation with a distinct morning peak (16, 38, 28, and 18% of episodes at 0-6, 6-12, 12-18, and 18-24 h, respectively, p < 0.001). In contrast, tachyarrhythmic episodes during beta-blocker therapy (n = 104) were equally distributed over time (22, 27, 24, and 27% of episodes at 0-6, 6-12, 12-18, and 18-24 h, respectively, p = 0.95). The circadian distribution of episodes was significantly different in patients with and those without beta blockade (p < 0.05). CONCLUSION Beta-adrenergic antagonists influence the circadian distribution of malignant ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. The blunted morning peak of tachyarrhythmic events during beta blockade supports the hypothesis that a sympathetic surge is involved in the circadian pattern of malignant arrhythmias.
Collapse
Affiliation(s)
- S Behrens
- Department of Cardiology and Pulmology, Klinikum Benjamin Franklin, Free University, Berlin, Germany
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Gödde P, Agrawal R, Müller HP, Czerski K, Endt P, Steinhoff U, Oeff M, Schultheiss HP, Behrens S. Magnetocardiographic mapping of QRS fragmentation in patients with a history of malignant tachyarrhythmias. Clin Cardiol 2009; 24:682-8. [PMID: 11594414 PMCID: PMC6654772 DOI: 10.1002/clc.4960241009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
BACKGROUND The identification of patients at increased risk for ventricular tachycardia or ventricular fibrillation (VT/VF) and sudden cardiac death has consequences for therapeutic options and thus may reduce mortality in patients with coronary artery disease (CAD). HYPOTHESIS We hypothesized that the intra-QRS fragmentation in magnetocardiographic recordings is increased in patients with CAD and with a history of VT/VF. METHODS Multichannel magnetocardiography (MCG) was carried out in 34 healthy controls, 42 patients with CAD without a history of VT/VF, and 43 patients with CAD and with a history of VT/VF. The intra-QRS fragmentation was quantified by a new fragmentation score. Its spatial distribution was investigated using two-dimensional (2-D) contour maps according to the sensor position of the 49-channel magnetogradiometer. RESULTS Patients with CAD and with a history of VT/VF had significantly increased QRS fragmentation compared with patients with CAD without VT/VF or controls (72.9+/-37.5, 48.5+/-14.3, and 42.5+/-7.8, respectively: p <0.05). The area of high fragmentation in 2-D contour maps was twice as large in patients with than in those without a history of VT/VF (represented by the number of MCG channels with high fragmentation: 26.3+/-15.5 vs. 12.4+/-9.9, p<0.0001). Patients prone to VT/VF could be identified with a sensitivity of 64% and a specificity of 90%. CONCLUSION In patients with CAD and with a history of VT/VF, intra-QRS fragmentation is increased and the area of high fragmentation in 2-D contour maps is enlarged. These findings may be helpful in identifying patients with CAD at risk for malignant tachyarrhythmias.
Collapse
Affiliation(s)
- P Gödde
- University Clinic Benjamin Franklin, Free Berlin University, 2nd Medical Clinic, Department of Cardiology and Pulmonary Disease, Berlin, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Nagele H, Behrens S, Eisermann C. Cardiac contractility modulation in non-responders to cardiac resynchronization therapy. Europace 2008; 10:1375-80. [DOI: 10.1093/europace/eun257] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
43
|
Behrens S, Bönnemann H, Modrow H, Kempter V, Riehemann W, Wiedenmann A, Odenbach S, Will S, Thrams L, Hergt R, Müller R, Landfester K, Schmidt A, Schüler D, Hempelmann R. Synthesis and Characterization. ACTA ACUST UNITED AC 2008. [DOI: 10.1007/978-3-540-85387-9_1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
|
44
|
Maier B, Röhnisch JU, Behrens S, Graf-Bothe C, Kuckuck H, Schoeller R, Schuehlen H, Theres H. Impact of Time of Admission on Treatment and Outcome of Patients with ST-Elevation Myocardial Infarction. Gesundheitswesen 2008. [DOI: 10.1055/s-0028-1086382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
45
|
Nägele H, Behrens S. Response to the Letter of de Cock et al. Pacing Clin Electrophysiol 2007. [DOI: 10.1111/j.1540-8159.2007.00859_2.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
|
47
|
Nägele H, Hashagen S, Azizi M, Behrens S, Castel MA. Analysis of terminal arrhythmias stored in the memory of pacemakers from patients dying suddenly. ACTA ACUST UNITED AC 2007; 9:380-4. [PMID: 17434892 DOI: 10.1093/europace/eum040] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
AIMS Stored electrograms or marker channels are available in most of modern cardiac pacemaker models. We sought to analyse these information to uncover terminal events of pacemaker patients dying suddenly. Method and results We made post-mortem pacemaker (PM) interrogations in 19 patients dying suddenly out of hospital between the years 1997 and 2005 (mean age 59 +/- 13 years, 90% males). The systems had activated arrhythmia monitoring algorithms. Indications of pacing were sick sinus syndrome in seven, AV-block in five, and heart failure due to asynchrony in seven cases. The interrogated pacemakers were CHORUS 7034 (n = 12), CONTAK TR (n = 2), and INSYNC III (n = 5). For interpretation stored marker channels and electrograms were analysed. The mean observation time after PM implantation prior death was 2.11 +/- 1.44 years, the mean left ventricular ejection fraction from the last available echo examination in the year prior death was 27.5 +/- 8%, mean age was 63 +/- 12 years. In 17/19 cases (89%), a tachycardia (most likely ventricular tachycardia) was found correlating to the time of death. The mean cycle length of the terminal arrhythmia was 307 +/- 144 (250-344) ms, corresponding to a heart rate of 195 +/- 95 (174-240) bpm. We found no evidence of specific pacemaker-related problems such as electronic failure, battery depletion, or undersensing. CONCLUSIONS Post-mortem analysis of arrhythmia monitoring of pacemaker patients revealed tachycardias (most likely ventricular tachycardia) to be related to sudden death. These findings give some insight in mechanisms of terminal events in this group.
Collapse
Affiliation(s)
- H Nägele
- St Adolfstift, Medical Clinic, Reinbek, Germany, Hamburger Str. 41, D-21465 Hamburg.
| | | | | | | | | |
Collapse
|
48
|
Abstract
AIMS Coronary sinus (CS) lead implantation is a technically challenging procedure owing to variable vein anatomies and a high dislocation rate. Therefore, CS lead technology has undergone evolutionary changes during the last 10 years. The mode of fixation has been a passive one up to now. We want to describe our first clinical experience with the newly available active fixation lead 4195 in terms of dislocation rate and stability of thresholds compared with conventional models. METHODS AND RESULTS From 1999 to February 2007, we implanted 403 CS leads in 368 patients. Leads were categorized into three different groups on the basis of their fixation mechanism: straight (Easytrak I and Situs OTW; n = 54), curved (Attain 4193 and 4194, Corox, Aescula, Situs ULD; n = 308), and active (Attain 4195; n = 41). Operative and follow-up data were prospectively noted and checked for significance between groups during the first 3 months after implantation. Kaplan-Meier analysis of long-term lead function was also performed. Straight and curved CS leads suffered from significantly more dislocations compared with active fixation (P < 0.001). The active fixation lead (4195) has a stable threshold over time compared with a significant rise after 24 h and thereafter in straight (62%) and curved leads (20%). However, retraction of an active fixation CS lead may be a difficult issue as outlined in two cases requiring pullback of a 4195 lead owing to phrenic nerve stimulation (one unsuccessful despite vigorous traction). CONCLUSION The active fixation lead 4195 using retention lobes yielded stable thresholds over time and seems to be superior to conventional leads in terms of dislocation. However, extraction may be a difficult or even impossible task.
Collapse
Affiliation(s)
- H Nägele
- Medical Department, St Adolfstift, Hamburgerstr. 41, D-21465 Reinbek, Germany.
| | | | | | | | | |
Collapse
|
49
|
Abstract
Rhabdomyolysis is a well known side effect of statin therapy. Several drugs may increase its risk by drug-drug interactions. In particular, patients with heart disease receive more and more different compounds to cope with all the pathomechanisms involved and may therefore be of high risk for side effects. We report a case of rhabdomyolysis in a patient with heart failure on a multi-drug regimen caused by a drug interaction between chronic statin therapy (simvastatin), amiodarone and newly administrated digitoxin. The patient recovered fully after cessation of simvastatin therapy, the other drugs were given continuously. Potential mechanisms of this event are discussed. Most interesting in this case is that rhabdomyolysis occurred only after starting digitoxin after long-term therapy with the statin.
Collapse
Affiliation(s)
- H Nägele
- St. Adolfstift Medical Clinic, Reinbek, Germany.
| | | | | | | |
Collapse
|
50
|
Laue H, Behrens S, Althaus M, Kraß S, Peitgen HO. Computergestützte Auswertung dynamischer MR-Daten mithilfe von Modellen der Kontrastmitteldynamik. ROFO-FORTSCHR RONTG 2007. [DOI: 10.1055/s-2007-977225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|